Telomir Pharmaceuticals, Inc. Common Stock (TELO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a cash flow conversion efficiency ratio of -0.357x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.77 Million) by net assets ($4.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TELO defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Telomir Pharmaceuticals, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Telomir Pharmaceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Telomir Pharmaceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Telomir Pharmaceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
|
0.156x |
|
Han Kook Capital Co. Ltd
KQ:023760
|
-0.137x |
|
Zevia Pbc
NYSE:ZVIA
|
0.003x |
|
PT Buana Artha Anugerah Tbk
JK:STAR
|
-0.003x |
|
Inpro SA
WAR:INP
|
-0.037x |
|
BIEN SPAREB.AS NK 34375
F:JX0
|
-0.180x |
|
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
|
-0.151x |
|
Les Docks des Pétroles d-Ambès - SA
PA:DPAM
|
0.067x |
Annual Cash Flow Conversion Efficiency for Telomir Pharmaceuticals, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see TELO stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $5.91 Million | $-3.69 Million | -0.624x | +92.09% |
| 2024-09-30 | $643.04K | $-5.07 Million | -7.885x | -602.39% |
| 2023-09-30 | $3.44 Million | $-3.86 Million | -1.123x | -324.51% |
| 2022-09-30 | $-937.28K | $-468.66K | 0.500x | -65.19% |
| 2021-09-30 | $-83.13K | $-119.40K | 1.436x | -- |
About Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macu… Read more